Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

Roivant Sciences Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ARBUTUS ANNOUNCES THAT IT IS CURRENTLY EVALUATING A RETURN OF CAPITAL TO SHAREHOLDERS FOR THE THIRD QUARTER OF CALENDAR YEAR 2026, IN CONJUNCTION WITH THE UPFRONT PAYMENT ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND VANCOUVER, BRITISH COLUMBIA, MARCH 03, 2026 (GLOBE NEWSWIRE) -- GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT SCIENCES LTD.

GENEVANT SCIENCES AND ARBUTUS BIOPHARMA ANNOUNCE $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ROIVANT'S BOARD OF DIRECTORS HAS APPROVED A $1 BILLION SHARE REPURCHASE PROGRAM, INCLUSIVE OF THE $500 MILLION AUTHORIZATION THAT WAS APPROVED IN JUNE 2025 ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND LONDON AND NEW YORK, MARCH 03, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT, AND ARBUTUS BIOPHARMA CORPORATION (NASDAQ: ABUS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON INFECTIOUS DISEASE, HAVE ENTERED INTO A $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA, INC. TO RESOLVE ALL U.S. AND INTERNATIONAL ENFORCEMENT ACTIONS INVOLVING MODERNA'S UNAUTHORIZED USE OF GENEVANT'S AND ARBUTUS' LNP DELIVERY TECHNOLOGY IN ITS COVID-19 VACCINES, INCLUDING S

ROIVANT ANNOUNCES GENEVANT SCIENCES' AND ARBUTUS BIOPHARMA'S $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA

FDA ASSIGNS PDUFA TARGET ACTION DATE IN THE THIRD QUARTER OF CALENDAR YEAR 2026 WITH LAUNCH EXPECTED AT THE END OF SEPTEMBER 2026 PRIORITY REVIEW SUPPORTED BY POSITIVE PHASE 3 VALOR RESULTS, THE FIRST POSITIVE 52-WEEK PLACEBO-CONTROLLED TRIAL IN DERMATOMYOSITIS IF APPROVED, BREPOCITINIB WOULD REPRESENT THE FIRST TARGETED THERAPY APPROVED FOR DERMATOMYOSITIS DURHAM, N.C., MARCH 03, 2026 (GLOBE NEWSWIRE) -- PRIOVANT THERAPEUTICS TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS ACCEPTED ITS NEW DRUG APPLICATION (NDA) FOR BREPOCITINIB FOR THE TREATMENT OF DERMATOMYOSITIS (DM) AND HAS GRANTED THE APPLICATION PRIORITY REVIEW.

PRIOVANT ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF NEW DRUG APPLICATION FOR BREPOCITINIB IN DERMATOMYOSITIS

BASEL, SWITZERLAND AND LONDON AND NEW YORK, FEB. 06, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS) AND REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER31, 2025.

ROIVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS) AND REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2025

DURHAM, N.C., FEB. 06, 2026 (GLOBE NEWSWIRE) -- PRIOVANT THERAPEUTICS TODAY ANNOUNCED POSITIVE RESULTS FROM THE PHASE 2 BEACON STUDY EVALUATING BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS). CS IS A HIGHLY MORBID, CHRONIC, AND DISFIGURING CONDITION WITH NO APPROVED THERAPIES, AND THE BEACON STUDY IS THE FIRST EVER INDUSTRY-SPONSORED PLACEBO-CONTROLLED TRIAL IN THE INDICATION TO READ OUT POSITIVELY.

PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)

WALTHAM, MASS., FEB. 06, 2026 (GLOBE NEWSWIRE) -- PULMOVANT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY COMMITTED TO TRANSFORMING THE LIVES OF PATIENTS WITH PULMONARY DISEASES, AND A ROIVANT (NASDAQ: ROIV) COMPANY, TODAY ANNOUNCED THAT IT HAS COMPLETED ENROLLMENT IN THE PHASE 2 PHOCUS CLINICAL TRIAL EVALUATING MOSLICIGUAT FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD), A PROGRESSIVE AND LIFE-THREATENING CONDITION WITH SIGNIFICANT UNMET MEDICAL NEEDS FOR PATIENTS.

PULMOVANT ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE 2 PHOCUS STUDY OF MOSLICIGUAT IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD)

BASEL, SWITZERLAND AND LONDON AND NEW YORK, JAN. 23, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON FRIDAY, FEBRUARY 6, 2026, TO REPORT ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED DECEMBER 31, 2026, AND PROVIDE A BUSINESS UPDATE.

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2025, AND PROVIDE BUSINESS UPDATE ON FRIDAY, FEBRUARY 6, 2026

BASEL, SWITZERLAND AND LONDON AND NEW YORK, DEC. 11, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY IS HOSTING AN INVESTOR DAY IN NEW YORK CITY. ROIVANT LEADERSHIP WILL HIGHLIGHT KEY PIPELINE UPDATES AND PROVIDE AN UPDATE ON THE COMPANY'S STRATEGY FOR LONG-TERM VALUE CREATION.

ROIVANT HIGHLIGHTS CONTINUED PIPELINE PROGRESS AND OUTLOOK FOR COMPANY'S NEXT PHASE OF GROWTH AT 2025 INVESTOR DAY

BASEL, SWITZERLAND AND LONDON AND NEW YORK, NOV. 10, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER30, 2025, AND PROVIDED A BUSINESS UPDATE. BREPOCITINIB 30 MG DEMONSTRATED CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT IMPROVEMENT COMPARED TO PLACEBO ON THE PRIMARY ENDPOINT AND ALL NINE KEY SECONDARY ENDPOINTS IN PHASE 3 VALOR STUDY IN DERMATOMYOSITIS (DM), WITH NDA FILING PLANNED FOR THE FIRST HALF OF CALENDAR YEAR 2026 BREPOCITINIB PROGRAM CONTINUES TO ADVANCE WITH RAPID ENROLLMENT IN PHASE 3 STUDY IN NON-INFECTIOUS UVEITIS (NIU) AND PROOF-OF-CONCEPT TRIAL IN CUTANEOUS SARCOIDOSIS (CS), WITH READOUTS EXPECTED IN THE FIRST HALF OF CALENDAR YEAR 2027 AND SECOND HALF OF CALENDAR YEAR 2026, RESPECTIVELY IMMUNOVANT STUDY IN UNCONTROLLED GRAVES' DISEASE (GD) PATIENTS TREATED FOR 24 WEEKS SHOWED FIRST-EVER POTENTIALLY DISEASE-MODIFYING OUTCOME WITH SIX-MONTH OFF-TREATMENT DATA.

ROIVANT REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDES BUSINESS UPDATE

NEW YORK, OCT. 27, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT (NASDAQ: IMVT) TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDE A BUSINESS UPDATE AT 8:00 A.M. ET ON MONDAY, NOVEMBER 10, 2025.

Roivant Sciences Ltd.

ROIV

Price

Financial Reports

No items found.

Press Releases

Roivant Sciences Ltd.

ROIV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ROIV